Clinical trials: Endocrine System Disorder
Graves Ophthalmopathy
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease).
- Trial name
- NCT01114503
- Testing
- Otelixizumab - low dose, Otelixizumab - medium low dose, Otelixizumab - medium high dose
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Type 2
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the…
- Trial name
- NCT01165983
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Depression, Diabetes
A Helping Hand Among Low-Income Patients
Study Hypotheses (Ho) and Research Questions (RQ): Ho1. AHH will significantly improve patient depression treatment acceptance/adherence and depression symptoms vs UC at 6 and 12 months post-baseline. Ho2.
- Conditions
- Depression, Diabetes, Heart Disease
- Trial name
- AHH (NCT02147522)
- Testing
- Self-care management
- Where
- 3 sites in United States
- Volunteers
- 348 people
- Sponsor
- University of Southern California
Type 2 Diabetes
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in…
- Trial name
- NCT00951899
- Testing
- Colesevelam, Diet, Metformin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Obesity, Diabetes Mellitus
Incentivizing Lifestyle Modification to Reduce Disease Burden
Specifically, the main objective of this pilot and feasibility study is to develop the infrastructure that will be used in a larger study that would be proposed at a later date. Hence, this study has two parts.
- Trial name
- NCT02945332
- Testing
- Required supervised walking, Non-required supervised walking, Fitbit Flex
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Diabetes Mellitus, Diabetes Mellitus, Type 2
Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes
The experimental approach in this study intends to investigate the role of hepatic glycogen content on nocturnal regulation of endogenous glucose production including the relative contributions of glycogenolysis and…
- Trial name
- NCT04416204
- Testing
- glycogen loading, No Glycogen Loading
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Pancreatic Cancer
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00691054
- Testing
- Abraxane
- Where
- 2 sites in United States, Singapore
- Volunteers
- 20 people
- Sponsor
- University of Miami
Diabetes Type 2
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
- Trial name
- DURATION-NEO-2 (NCT01652729)
- Testing
- Exenatide once weekly suspension, Sitagliptin
- Where
- 60 sites in United States
- Volunteers
- 365 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Background: Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time.
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms
- Trial name
- NCT02487095
- Testing
- Topotecan, VX-970 (M6620)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Drug Use, Alcohol Use
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
This study will assess Specialized Community Disease Management (SCDM), an intervention which employs various evidence-based strategies to engage substance using co-morbid patients while in the hospital and follow them into the…
- Conditions
- Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia
- Trial name
- NCT02059005
- Testing
- Specialized Community Disease Management, Treatment As Usual
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Treatment Research Institute
Pain, Hypogonadism
Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception
Naturally occurring opiates (endorphins) decrease testosterone levels by inhibiting the synthesis of gonadotropin releasing hormone (GnRH) and also inhibiting testosterone synthesis by the testes.
- Trial name
- TAP (NCT00351819)
- Testing
- AndroGel
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Boston University
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or…
- Trial name
- DECLARE-TIMI58 (NCT01730534)
- Testing
- Dapagliflozin 10 mg
- Where
- 805 sites in United States, Argentina and 32 more
- Volunteers
- 17,190 people
- Sponsor
- AstraZeneca
Acromegaly
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial (OPTMAL; NCT03252353), oral octreotide capsules demonstrated sustained biochemical…
- Trial name
- MPOWERED (NCT02685709)
- Testing
- Octreotide capsules
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 146 people
- Sponsor
- Chiasma, Inc.
Hormone Deficiency, Aging
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body.
- Trial name
- NCT01410799
- Testing
- Growth Hormone Releasing Hormone (GHRH )
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Wound Heal, Peripheral Artery Disease
Safety and Efficacy of the Noxsano Wound Care Bandage
This study is a prospective, interventional, non-randomized study designed to assess the safety and efficacy of the Noxsano Bandage (study device) in healthy subjects and wound care subjects with a diabetic lower extremity…
- Conditions
- Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot
- Trial name
- NCT04123093
- Testing
- Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Pancreatic Cancer, Bile Duct Cancer
Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with pancreaticoduodenectomy.
- Trial name
- EPIPD (NCT01256034)
- Testing
- Oral IMPACT
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Chiba University
Type 2 Diabetes
Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor (ANICGM)
Diabetes mellitus (DM) affects 30 million people in the United States. To achieve glucose control, most patients are prescribed glucose meters by their physicians.
- Trial name
- NCT04166032
- Testing
- Alertgy non-invasive continuous glucose monitoring device (ANICGM)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.